<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04721626</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00039230</org_study_id>
    <nct_id>NCT04721626</nct_id>
  </id_info>
  <brief_title>Topical Antisepsis in Head and Neck Cancer Surgery</brief_title>
  <official_title>A Topical Antiseptic Bundle for Decreasing Surgical Site Infection in Head and Neck Cancer Patients: Perioperative Effects on the Oral Microbiome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm prospective trial of an intra- and postoperative topical antiseptic&#xD;
      bundle. The study will recruit patients undergoing an open surgical resection of the upper&#xD;
      aerodigestive tract requiring a planed vascularized reconstruction, which may be either&#xD;
      pedicled and/or free flap. The objectives are to evaluate antimicrobial effects of a&#xD;
      perioperative topical antiseptic bundle and to identify the source of surgical site infection&#xD;
      as well as the rate of 30-day adverse events in head and neck cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design is a single-arm prospective trial. It will investigate the microbial effects&#xD;
      of topical antisepsis on upper aerodigestive tract and reconstructive surgery in head and&#xD;
      neck cancer patients. The primary hypothesis is that topical antisepsis will significantly&#xD;
      decrease oral bacterial load and the presence of pathogenic organisms. Secondary outcomes&#xD;
      will include identification of the source of the infectious bacterial organisms, surgical and&#xD;
      non-surgical site infections, serious topical antisepsis-related complications, serious&#xD;
      adverse events, and hospital revisits. The study populations will include head and neck&#xD;
      cancer patients age 18 or greater undergoing head and neck reconstructive surgery in which&#xD;
      there is a communication between the upper aerodigestive tract and the cervical skin which&#xD;
      requires a planned vascularized reconstruction, either a regional pedicled flap or a free&#xD;
      tissue transfer. The accrual goal will be 25 patients. Data collection will occur in both the&#xD;
      inpatient and outpatient settings. Patients will be enrolled during their preoperative clinic&#xD;
      visit. Each patient will be followed for study outcomes until 30 days postoperatively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Oral microbial abundance in preoperative samples measured by quantitative bacteriology.</measure>
    <time_frame>Baseline (immediately preoperative)</time_frame>
    <description>Bacteria will be measured as colony forming unit/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral microbial abundance in preoperative samples measured by 16s sequencing.</measure>
    <time_frame>Baseline (immediately preoperative)</time_frame>
    <description>This will be measured by the number of operational taxonomic units.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral microbial abundance in intraoperative samples prior to antiseptic irrigations measured by quantitative bacteriology.</measure>
    <time_frame>During surgery before wound irrigation</time_frame>
    <description>Bacteria will be measured as colony forming unit/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral microbial abundance in intraoperative samples prior to antiseptic irrigations measured by 16s sequencing.</measure>
    <time_frame>During surgery before wound irrigation</time_frame>
    <description>This will be measured by the number of operational taxonomic units.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral microbial abundance in samples after intraoperative antiseptic irrigations measured by quantitative bacteriology.</measure>
    <time_frame>During surgery following wound irrigation</time_frame>
    <description>Bacteria will be measured as colony forming unit/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral microbial abundance in samples after intraoperative antiseptic irrigations measured by 16s sequencing.</measure>
    <time_frame>During surgery following wound irrigation</time_frame>
    <description>This will be measured by the number of operational taxonomic units.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral microbial abundance in postoperative samples measured by quantitative bacteriology.</measure>
    <time_frame>Postoperative day 3.</time_frame>
    <description>Bacteria will be measured as colony forming unit/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral microbial abundance in postoperative samples measured by 16s sequencing.</measure>
    <time_frame>Postoperative day 3.</time_frame>
    <description>This will be measured by the number of operational taxonomic units.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of subjects with surgical site infection</measure>
    <time_frame>30 days</time_frame>
    <description>Surgical site infection diagnosis must be performed by the attending physician and occur within 30 days post-operatively. Diagnosis will include either: 1) purulent drainage from incision, 2) incision spontaneously dehisced or opened by the surgeon because of infection, 3) abscess or other evidence of infection involving a deep incision; or 4) surgical site infection diagnosis by the surgeon.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with 30-day hospital revisits</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Defined as any unanticipated hospital readmission within 30 days of the index surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with non-surgical site infections</measure>
    <time_frame>30 days</time_frame>
    <description>An infection of the tracheobronchial tree, urinary tract, or blood, as determined by the isolation of pathogenic microorganisms from these sites in the setting of clinical signs and symptoms of infection in accordance with the International Nosocomial Infection Control Consortium (INICC) criteria. Pneumonia, clinical sepsis, and symptomatic urinary tract infection without an identified pathogenic microorganism may be diagnosed according to the INICC guidelines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of subjects with serious topical antisepsis-related complications</measure>
    <time_frame>30 days</time_frame>
    <description>Serious adverse event is deemed related to or probably related to the topical antiseptic agent. When topical antiseptic-related complications are suspected by the attending physician, the infectious disease service will be consulted, and a serious topical antiseptic-related complication will be diagnosed based on their recommendations.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorhexidine Gluconate</intervention_name>
    <description>Preoperative: The patient's dentition, or mandibular alveolus in the absence of dentition, will be brushed for two minutes with 0.12% chlorhexidine gluconate.&#xD;
Intraoperative: The wound will be irrigated for 60 seconds with 0.05% chlorhexidine after it is irrigated with povidone-iodine.&#xD;
Postoperative: Patients will swish and spit/suction 15mL 0.12% Chlorhexidine Gluconate (CHG) oral rinses for 30 seconds every six hours for two days (8 total administrations)</description>
    <other_name>Peridex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Povidone-iodine</intervention_name>
    <description>Preoperative: The oral cavity and oropharyngeal mucosa as well as the nasal vestibules will be coated with 5% povidone-iodine which will stand for at least three minutes prior to incision.&#xD;
Intraoperative: The wound will be irrigated for 60 seconds with 10% povidone-iodine.</description>
    <other_name>Iodopovidone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetracycline Ointment</intervention_name>
    <description>Postoperative: ~10g 3% tetracycline ointment will be placed into the oral cavity to coat the dorsal tongue and any oral suture lines every six hours for two days (8 total doses).</description>
    <other_name>Adoxa CK</other_name>
    <other_name>Adoxa TT</other_name>
    <other_name>Amzeeq</other_name>
    <other_name>Cleeravue-M</other_name>
    <other_name>Zilxi</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Swabs will be taken of the mouth, nose, surgical site and environment. Recombinant 16s DNA&#xD;
      (16 s) sequencing will be used to identify bacteria present at those sites.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Eligibility: Patients â‰¥ 18 years old planned to undergo surgical resection of the upper&#xD;
        aerodigestive tract for a cancer-related indication and requiring reconstruction which may&#xD;
        be either a regional pedicled and/or free tissue transfer.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years or older.&#xD;
&#xD;
          2. Planned to undergo an open surgical procedure requiring a communication between the&#xD;
             upper aerodigestive tract and cervical skin with a planned vascularized&#xD;
             reconstruction, which may be either a regional pedicled and/or free flap.&#xD;
&#xD;
          3. Subsites reconstructed must include at least one of the following: oral cavity,&#xD;
             oropharynx, larynx, hypopharynx, and/or cervical esophagus.&#xD;
&#xD;
          4. Eligible patients must be undergoing surgery related to treatment for head and neck&#xD;
             cancer. This includes immediate reconstruction after tumor ablation as well as&#xD;
             reconstruction for delayed cancer-related indications including radionecrosis or&#xD;
             improvement in functional outcomes after head and neck cancer treatment.&#xD;
&#xD;
          5. Voluntary written consent must be given before performance of any study-related&#xD;
             procedure not part of standard medical care, with the understanding that consent may&#xD;
             be withdrawn by the subject at any time without prejudice to future medical care.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. True allergy to any study-related medications&#xD;
&#xD;
          2. Active infection at the time of surgery&#xD;
&#xD;
          3. Pregnancy or actively breastfeeding mothers. Female subjects who are both lactating&#xD;
             and breastfeeding or of childbearing potential who have a positive serum test during&#xD;
             screening.&#xD;
&#xD;
          4. Patients incarcerated in state or federal penitentiaries&#xD;
&#xD;
          5. Patients with a serious medical or psychiatric illness likely to interfere with&#xD;
             participation in this clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Zenga, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical College of Wisconsin Cancer Center Clinical Trials Office</last_name>
    <phone>414-805-8900</phone>
    <email>cccto@mcw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Froedtert Hospital &amp; the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Zenga, MD</last_name>
      <phone>414-805-0505</phone>
      <email>jyzenga@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Zenga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 19, 2021</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Joseph Zenga</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
    <mesh_term>Povidone-Iodine</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Povidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

